SCHEMBL5675820

SCHEMBL5675820

CCCC(=O)OC[C@H]1O[C@H](O)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H]1OC(=O)CCC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.67
▸ CA12 O43570 11/20 0.44
▸ CA1 P00915 11/20 0.44
▸ CA2 P00918 11/20 0.44
▸ CA9 Q16790 11/20 0.44
▸ CA14 Q9ULX7 8/20 0.44
▸ NR3C1 P04150 1/20 0.38
▸ FYN P06241 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ CYP2D6 P10635 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ NLRP3 Q96P20 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ TLR4 O00206 1/20 0.35
▸ PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20581575 1.00 MAPT (0.67) MAPTCA12CA1CA2CA9
SCHEMBL23855305 1.00 MAPT (0.67) MAPTCA12CA1CA2CA9
SCHEMBL29477379 1.00 MAPT (0.67) MAPTCA12CA1CA2CA9
SCHEMBL22107791 0.96 MAPT (0.62) MAPTCA12CA1CA2CA9
SCHEMBL27951344 0.91 MAPT (0.64) MAPTCA12CA1CA2CA9
SCHEMBL30163231 0.91 MAPT (0.64) MAPTCA12CA1CA2CA9
SCHEMBL28687895 0.91 MAPT (0.56) MAPTCA12CA1CA2CA9
SCHEMBL15659417 0.90 MAPT (0.62) MAPTCA12CA1CA2CA9
SCHEMBL15659416 0.90 MAPT (0.62) MAPTCA12CA1CA2CA9
SCHEMBL19304981 0.89 MAPT (0.61) MAPTCA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521761-B1 TREATMENT OF CONGENITAL DISORDERS OF GLYCOSYLATION (CDG) USING MANNOSE MARQUARDT THORSTEN (DE) 2006-01-11 — — EP disclosed
EP-1521761-A2 TREATMENT OF CONGENITAL DISORDERS OF GLYCOSYLATION (CDG) USING MANNOSE Marquardt, Thorsten (DE) 2005-04-13 — — EP disclosed
WO-2003104247-A2 TREATMENT OF CONGENITAL DISORDERS OF GLYCOSYLATION (CDG) USING MANNOSE SHS GESELLSCHAFT FÜR KLINISCHE ERNÄHRUNG MBH (DE) 2003-12-18 — — WO disclosed
Send feedback